Ivanova Daria, Siu Ricky, Roointan Mehraein, Sahoo Saswat, Enbar Tom, Livingston Jessica, Faiz Maryam, Morshead Cindi M
Department of Surgery, Division of Anatomy, University of Toronto; Institute of Medical Science, University of Toronto.
Department of Surgery, Division of Anatomy, University of Toronto.
J Vis Exp. 2024 Nov 29(213). doi: 10.3791/66965.
Ectopic expression of neurogenic factors in vivo has emerged as a promising approach for replacing lost neurons in disease models. The use of neural basic helix-loop-helix (bHLH) transcription factors via non-propagating virus-like particle systems, including retrovirus, lentivirus, and adeno-associated virus (AAV), has been extensively reported. For in vivo experiments, AAVs are increasingly used due to their low pathogenicity and potential for translatability. This protocol describes two AAV systems for investigating the ectopic expression of transcription factors in transduced cells post-ischemic stroke. In both systems, Neurod1 expression is controlled by the short GFAP (gfaABC(1)D) promoter, which is upregulated in reactive astrocytes post-stroke as well as in endogenous neurons when combined with neurogenic factor expression. In the ischemic stroke model described, focal ischemia is induced by injecting endothelin-1 (ET-1) into the motor cortex of mice, creating a lesion surrounded by reactive GFAP-expressing astrocytes and surviving neurons. Intracerebral injections of AAV are performed to ectopically induce the expression of Neurod1 in the subacute (7 days) and chronic (21 days) phases post-stroke. Within weeks following AAV injection, a significantly higher number of neurons among transduced cells are identified in mice ectopically expressing Neurod1 compared to mice receiving AAV control viruses. The AAV-based strategies used replicated observed outcomes of increased numbers of neurons expressing the reporter gene in a model of mild-to-moderate cortical stroke. This protocol establishes a standard platform for exploring the effects of ectopic expression of transcription factors delivered with AAV-based systems, contributing to the understanding of neurogenic factor expression in the context of stroke.
在体内异位表达神经源性因子已成为在疾病模型中替代丢失神经元的一种有前景的方法。通过非增殖性病毒样颗粒系统(包括逆转录病毒、慢病毒和腺相关病毒(AAV))使用神经碱性螺旋-环-螺旋(bHLH)转录因子的情况已有大量报道。对于体内实验,由于AAV致病性低且具有转化潜力,其使用越来越广泛。本方案描述了两种用于研究缺血性中风后转导细胞中转录因子异位表达的AAV系统。在这两种系统中,Neurod1的表达由短GFAP(gfaABC(1)D)启动子控制,该启动子在中风后反应性星形胶质细胞中上调,并且在与神经源性因子表达结合时在内源性神经元中也上调。在所描述的缺血性中风模型中,通过向小鼠运动皮层注射内皮素-1(ET-1)诱导局灶性缺血,形成一个由表达反应性GFAP的星形胶质细胞和存活神经元包围的损伤区域。在中风后的亚急性期(7天)和慢性期(21天)进行脑内注射AAV,以异位诱导Neurod1的表达。在注射AAV后的几周内与接受AAV对照病毒的小鼠相比,在异位表达Neurod1的小鼠中转导细胞中的神经元数量显著更多。所使用的基于AAV的策略在轻度至中度皮质中风模型中复制了观察到的报告基因表达神经元数量增加的结果。本方案建立了一个标准平台,用于探索基于AAV系统递送的转录因子异位表达的影响,有助于理解中风背景下神经源性因子的表达。